Disc Medicine (IRON) Assets Average (2020 - 2026)
Disc Medicine (IRON) reported Assets Average of $778.5 million for Q1 2026, up 29.11% year-over-year from $603.0 million in Q1 2025, and up 8.33% on a QoQ basis from $718.7 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Assets Average data on file, last reported at $778.5 million in Q1 2026.
- Quarterly Assets Average rose 29.11% year-over-year to $778.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $778.5 million (up 29.11% YoY) and the FY2025 annual result came in at $651.8 million, up 50.75% from the prior year.
- Assets Average grew to $778.5 million in Q1 2026 per IRON's latest filing, from $718.7 million in the prior quarter.
- Across five years, Assets Average topped out at $778.5 million in Q1 2026 and bottomed at $108.3 million in Q1 2022.
- The 5-year median for Assets Average is $380.3 million (2023), against an average of $412.1 million.
- The widest annual swing landed in 2022, when Assets Average slumped 34.32%; it then soared 246.76% in 2023.
- Tracing IRON's Assets Average over 5 years: stood at $153.1 million in 2022, then surged by 143.11% to $372.2 million in 2023, then surged by 33.23% to $496.0 million in 2024, then soared by 44.9% to $718.7 million in 2025, then increased by 8.33% to $778.5 million in 2026.
- Per Business Quant, the three latest IRON Assets Average figures stand at $778.5 million (Q1 2026), $718.7 million (Q4 2025), and $647.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | 778.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 778.55 Mn |
| Dec 31, 2025 | 718.67 Mn |
| Sep 30, 2025 | 647.76 Mn |
| Jun 30, 2025 | 687.16 Mn |
| Mar 31, 2025 | 603.02 Mn |
| Dec 31, 2024 | 495.96 Mn |
| Sep 30, 2024 | 502.68 Mn |
| Jun 30, 2024 | 432.20 Mn |
| Mar 31, 2024 | 361.09 Mn |
| Dec 31, 2023 | 372.25 Mn |
| Sep 30, 2023 | 380.34 Mn |
| Jun 30, 2023 | 313.98 Mn |
| Mar 31, 2023 | 221.99 Mn |
| Dec 31, 2022 | 153.12 Mn |
| Sep 30, 2022 | 109.68 Mn |
| Jun 30, 2022 | 118.81 Mn |
| Mar 31, 2022 | 108.35 Mn |
| Dec 31, 2021 | 123.97 Mn |
| Sep 30, 2021 | 163.98 Mn |
| Jun 30, 2021 | 180.90 Mn |
| Mar 31, 2021 | 98.85 Mn |
| Dec 31, 2020 | 65.34 Mn |